•Ly-8 inhibits various coronaviruses, including severe acute respiratory syndrome coronavirus 2, in vitro. •Ly-8 did not ...

Latus’ other lead gene therapy uses its AAV-Ep+ capsid to target ependymal cells as well as neurons. Ependymal cells secrete proteins into the cerebrospinal fluid. Co-opting this function ...

Sangamo Therapeutics Inc., a genomic medicine company, has entered into a license agreement with Eli Lilly and Company.

LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...

Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...

The FDA granted priority review, with a decision expected by 19 June 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...

Then, they investigated which chromosomes encoded the mimicked proteins. “One of the most interesting things to us was that, when we looked at chromosomes across the genome, viruses tended to avoid ...

Lenacapavir 463.5mg/1.5mL (309mg/mL); soln for SC inj; preservative-free. Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between ...